



BY THE NUMBERS



3

Corporate Centers

Cambridge, Mass;
Beijing, China; and
Basel, Switzerland



8,000⁺

Colleagues Globally in

30 Countries



45

Countries

to date included in
clinical development

16

**Approved
Medicines***



**16 approved in China; 1 approved
in 47 markets globally*

3

**Internally
Discovered**

Approved Medicines



**Commercial
Organization
in China,
North America
and Europe**



800⁺

Oncology Research Team



~50

Clinical and Commercial Assets



47

**Markets where BTK inhibitor
Zanubrutinib is Approved**

50⁺

**Preclinical
Programs**

~50%

**with First-in-Class or
Best-in-Class Potential**



2

**Manufacturing Centers in
China. Construction underway
for new U.S. flagship facility.**